Introduction
The Shwachman-Diamond syndrome (SDS) (OMIM 260400) is an autosomal recessive multisystem disorder characterized by exocrine pancreatic dysfunction, mild neutropenia and may be associated with metaphyseal dysostosis, mild intellectual retardation, or various other organ dysfunctions. 1 The SBDS gene, located on chromosome 7q11, is associated with the disease. 2 SBDS protein is an essential cofactor for elongation factor 1 (EFL1), and together they directly catalyze eIF6 release from nascent 60S subunits of the ribosome by a mechanism requiring both GTP binding and hydrolysis. 3 4 The latter are the main causes of early death and warrant a hematopoietic stem cell transplantation. 5 No risk factors for these complications have been identified so far, although leukemia appears in the literature to be more frequent in males. 1;6;7 This prompted us to analyze a cohort of 102 genotyped patients with SDS belonging to 93 families, for which exhaustive clinical features, hematological and biological parameters have been collected over a median follow-up of 11.6 years.
Design and Methods

Patients
Patients included in this study were all registered in the French severe chronic neutropenia registry. The registry was initially created in 1993; since then, enrollment has been prospective. All types of congenital neutropenia were included 8 . Since 2008, the register was certified as a national registry by the health authorities, and completeness of cases was ascertained by controlling multiple sources. Thirty-five French pediatric hematology-oncology and gastro enterology units participated to this register. Data monitoring, based on medical charts, was done by a clinical research associate who visited each centre yearly. The patient must provide written informed consent to be included in the registry. Several reports of the register are available elsewhere 4;5;9-11 The common definition of SDS was used. 1 Briefly, SDS was diagnosed in patients with both neutropenia (with at least one complete blood count showing an absolute neutrophil count below 1.5 G/L) and exocrine pancreatic deficiency. In addition to this phenotype, recessive mutations of the SBDS gene were considered as diagnostic criteria of SDS. Of the 111 patients included in the registry with SDS diagnosis, 105 patients were genotyped. No mutations were found in two patients and one patient was excluded because of lack of phenotypic information. Thus, this study involved 102 patients, all with proven SBDS mutations.
Clinical investigation
Demographic, auxologic, nutritional status, hematological parameters, liver tests, immunological tests and infectious status were recorded. Septicemia, cellulitis, bacterial or fungal pneumonia, osteitis, and liver abscess were considered as severe infections and were systemically recorded. Immunoglobulin levels were analyzed according to age. 12 Developmental retardation was considered as severe if the patient was unable to attend a normal school, even late, and thus required special schooling. Prematurity was defined by a gestational age below 37
weeks, intrauterine growth retardation as a birth weight below 3 standard deviations (SD) for gestational age, and severe gastrointestinal complications as the need for nutritional support, either by enteral route with gastrostomy or by parenteral route. Orthopedic complications were considered to have occurred when orthopedic surgery (i.e. for hip dysplasia or scoliosis) was required. Age at diagnosis was defined by the age at the first pathological manifestation leading to the diagnosis of SDS.
Definition of hematological features and hematological complications
Initial complete blood count (CBC) value was the median value of the three first CBC collected in the life of the patients. Baseline CBC were considered if they were collected during routine consultations, with the exception of periods with granulocyte colony-stimulating factor (G-CSF) therapy and any hematological complications defined below. Because neutropenia is part of the definition of the disease, hematological complications take into account a severe dysfunction in other hematopoietic lineages, i.e. anemia or thrombocytopenia. Severe cytopenia (SC) was considered in cases of profound anemia (hemoglobin [Hb]
< 7g/dL) or profound thrombocytopenia (platelets < 20 G/L). The classification of SC was based on three criteria: bone marrow morphology and differential count, bone marrow cytogenetics and the duration of SC (less or more than 3 months). Bone marrow smears were centrally reviewed (OF) and classified according to the 2008 WHO classification, which is applicable to define acute leukemia and myelodysplastic syndrome (MDS). [13] [14] [15] Indeed, the complications were categorized as follows: a) malignant definitive SC, 11 .
SBDS sequence analysis
The patients or their parents gave their written informed consent for genetic testing. Genomic DNA was extracted from blood with standard procedures. The coding sequence and exon-intron boundaries of the SBDS gene were amplified by using the primers and polymerase chain reaction (PCR) conditions described by Boocock et al. 2 
Results
Demographic features and extra-hematopoietic characteristics
One hundred and two patients were studied. There was a slight male predominance (58 males; 57%). The median follow-up was 11.6 years (p25: 6.2 years -p75: 20 years), corresponding to 1446 person-years.
The 102 patients belonged to 93 distinct families. There were eight multiplex families, with two cases in seven families and three cases in one family. Median age at diagnosis was 0.55 years (p25: 0.18 years - 
Immuno-hematological features and infectious events
At diagnosis of SDS, the initial absolute neutrophil count (ANC) was 0.82 G/L (p25: 0.5 -p75: 1.7 G/L).
The median hemoglobin level was 11.4 g/dL (p25: 9.9 g/dL -p75 12. The median hemoglobin level was 11.7 g/dL (p25: 11.1 g/dL -p75 12.4 g/dL) and the median platelet count was 185 G/L (p25: 145 G/L -p75 238 G/L). During routine follow-up, 28 patients had low blood cell count values with 19 patients with median ANC below 0.5 G/L, 11 with a platelet count below 100 G/L and 7 with chronic anemia (hemoglobin below 9 g/dL). Bone marrow smears were available at baseline for 81 patients and granulopoietic blockage was observed in 20 patients (24.7%) while the others had differential counts within the normal range. Of note, routine bone marrow smears commonly presented granulopoietic abnormalities, with condensed chromatin and nuclear hyposegmentation (online supplementary figure 2 ).
Among the 81 patients with assessable immunoglobulin levels, one patient had low values (between -2SD and -3SD for age), but did not require immunoglobulin infusions. In contrast, polyclonal hypergammaglobulinemia was found in 52 patients (65%). The median lymphocyte count was 3.3 G/L (p25: 2.5 G/L -p75: 4.5 G/L).
Forty-three patients presented at least one episode of severe infection (42%). Median age at the first infection was 9.6 years (p25:2.4 years -p75: 16.9 years). The Kaplan-Meier plot (data not shown) showed that first severe infections were most frequent in childhood but continued to appear until the fourth decade.
A total of 72 severe infections were recorded and consisted of pneumonia in 30 G-CSF was used to prevent infections in 17 patients (in addition to its use for SC or in a post-transplant period), at a mean dose of 4.8 µg/kg (0.5-10 µg/kg). In most cases, G-CSF was used "on demand", i.e.
when an infection occurred. Only seven patients received long-term G-CSF therapy. HSCT was performed in 12 patients, for malignant (n=6) or non-malignant (n=6) SC as reported previously. 5 Seventeen deaths were recorded (15%), at a median age of 6.5 years (min-max: 0.2 -33.7 years). The survival plot showed higher mortality rates before five years of age and also in the third decade and the 20-years survival rate observed was 85% (95% CI: 76%-92%) (Supplementary figure 3) . The two deaths, not related to a SC, were the consequence a measles infection with a myocardiopathy, and a traffic injury, potentially provoked by orthopedic difficulty at age of thirteen.
SBDS mutations and genotype-phenotype relationships
The mutational spectrum in the 93 probands is reported in tables 2A and 2B. 10-year and 20-year risks of SC were 0%, 12.6 %, 58.6 % and 6.2%, 34.4% and 58.6%, respectively, in the three groups (P<0.0001, figure 2) . Lastly, the three groups also had a different dynamic of severe hematological complications as the high-risk group was exposed in the first decade, the intermediate-risk group later, with SC presenting during the second decade, while the low-risk group presented SC in their third decade.
Discussion
We studied a large cohort of 102 patients with SDS through our national registry. The long-term follow-up period allowed us to observe the hematological complications and to identify risk factors for SC.
To describe and to classify the hematological complications, we reviewed for all patients all the hematological parameters obtained longitudinally, the complete blood counts, the bone marrow smears myelodysplasia, leukemia and cytogenetic abnormalities. The situation described as cytopenia was also named by several authors as 'aplastic anemia', 17-23 despite many cases not fulfilling the classical criteria of severe aplastic anemia. 24 In SDS, an additional complexity is related to cytogenetic abnormalities observed incidentally during routine bone marrow surveillance. Two recurrent cytogenetic anomalies are observed, i(7)(q10) and del(20q), which can be indolent and eventually transient. [25] [26] [27] [28] [29] [30] [31] [32] [33] But the same abnormalities can also announce or be associated with a frank malignant outcome, [34] [35] [36] as we observed in two cases in this survey. In addition to i(7)(q10) and del(20q), we observed a same indolent profile in two patients, one with t(16;20) in addition to i(7)(q10) and one with a complex abnormality of the chromosome 9 (table 1) .
With regards to the difficulties in classifying the hematological complications undoubtedly related to the underlying disease, our work shows that the WHO classification of myelodysplasia can be applied to define the malignant complications of SDS [13] [14] [15] but needs to be completed by a category which can be simply defined as non-malignant SC, a category frequently named 'aplastic anemia'. [17] [18] [19] [20] [21] [22] [23] The terminology non-malignant SC was preferred to aplastic anemia, because routine bone marrow of SDS patients exhibited dysgranulopoeitic features or abnormalities of granulopoeitic maturation. As in Fanconi anemia, the dyserythropiesis hyposegmentation or condensed chromatine have not be considered as a sign of myelodysplasia, 37 except if it was observed in more than 50% of the neutrophils.
Indeed, the hematological complications need to encompass mild abnormalities constituted by the incidental detection of cytogenetic clone on bone marrow and by a transient dysfunction of hematopoiesis.
In such a case, spontaneous recovery is a key feature and needs to be observed by month three.
We then analysed the risk factors that may influence the occurrence of severe hematological complications, as they constitute so far the major causes of early death in patients with SDS. First, we analysed the relationships between the genotype and the occurrence of hematological complications. Until now, only four studies [38] [39] [40] [41] had both reported information about SBDS genotypes and a survey of patients including cases with SC. These four studies represent a total of 47 patients, among whom nine cases of malignant SC and two cases of non-malignant SC were observed, showing no particular association between genotype and SC. In this large cohort of 102 genotyped patients, we excluded a correlation between the genotype and the development of SC. This is not surprising since the two recurrent genotypes are observed in two-third of patients.
Secondly, we analysed hematological and clinical parameters. Our analysis showed that the prognostic factors of SC are significantly associated with the age at first symptoms and with hematological parameters, but did not correlate with gender or with other associated features characterizing the disease.
This led us to propose a classification of the severity of SDS based on the first blood counts (taking into account the first 3 CBC in order to exclude outlier values) and on the age of diagnosis (< or ≥ 3 months).
Patients diagnosed as SDS before the age of three months and with low hematological parameters at diagnosis have a higher risk of major hematological complications than patients diagnosed after three months and without low values of CBC, or with only one of these features. Consequently, the occurrence of SC was respectively in the two groups 13% and 0% after 10 years and 59% and 33% after 20 years of evolution.These results need to be validated by other studies on different cohorts of patients but it offers a simple way to identify patients at high-risk of severe hematological complications, at the time of their diagnosis.
Early identification of patients at risk for hematologic complications may be useful if any consider the possibility offered by the hematopoietic stem cell transplantation (HSCT). To date HSCT is proposed only in case of severe cytopenia 42 . But the results of transplants appear highly contrasted, according to the indication of the graft. Despite the small number, a significant difference in survival between patients receiving HSCT for non malignant SC and those undergoing the procedure for leukemic transformation. Mrs Grosjean for her support. This study is a study from the centre de reference des deficits immunitaires héréditaires (CEREDIH: the French National Reference Center for Primary Immune Deficiencies, http://www.ceredih.fr) and has been supported by the Société d'Hémato Immunologie pédiatrique.
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